Tadalafil Mylan

Nazione: Unione Europea

Lingua: inglese

Fonte: EMA (European Medicines Agency)

Compra

Foglio illustrativo Foglio illustrativo (PIL)
30-06-2022
Scheda tecnica Scheda tecnica (SPC)
30-06-2022

Principio attivo:

tadalafil

Commercializzato da:

Mylan Pharmaceuticals Limited

Codice ATC:

G04BE08

INN (Nome Internazionale):

tadalafil

Gruppo terapeutico:

Urologicals

Area terapeutica:

Erectile Dysfunction

Indicazioni terapeutiche:

Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Mylan is not indicated for use by women.

Dettagli prodotto:

Revision: 15

Stato dell'autorizzazione:

Authorised

Data dell'autorizzazione:

2014-11-21

Foglio illustrativo

                                61
B. PACKAGE LEAFLET
62
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TADALAFIL MYLAN 2.5 MG FILM-COATED TABLETS
tadalafil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Tadalafil Mylan is and what it is used for
2.
What you need to know before you take Tadalafil Mylan
3.
How to take Tadalafil Mylan
4.
Possible side effects
5.
How to store Tadalafil Mylan
6.
Contents of the pack and other information
1.
WHAT TADALAFIL MYLAN IS AND WHAT IT IS USED FOR
Tadalafil Mylan is a treatment for adult men with erectile
dysfunction. This is when a man cannot get, or
keep a hard, erect penis suitable for sexual activity. Tadalafil has
been shown to significantly improve the
ability of obtaining a hard erect penis suitable for sexual activity.
Tadalafil Mylan contains the active substance tadalafil which belongs
to a group of medicines called
phosphodiesterase type 5 inhibitors. Following sexual stimulation
Tadalafil Mylan works by helping the
blood vessels in your penis to relax, allowing the flow of blood into
your penis. The result of this is
improved erectile function. Tadalafil Mylan will not help you if you
do not have erectile dysfunction.
It is important to note that tadalafil does not work if there is no
sexual stimulation. You and your partner will
need to engage in foreplay, just as you would if you were not taking a
medicine for erectile dysfunction.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE TADALAFIL MYLAN
DO NOT TAKE TADALAFIL MYLAN
-
if you are allergic to tadalafil or any of the other ingredie
                                
                                Leggi il documento completo
                                
                            

Scheda tecnica

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Tadalafil Mylan 2.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 2.5 mg tadalafil.
_Excipient with known effect:_
Each film-coated tablet contains 29.74 mg of lactose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
A light yellow, film-coated, round, biconvex tablet (5.1 ± 0.3 mm)
debossed with ‘M’ on one side of the
tablet and ‘TL over 1’ on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of erectile dysfunction in adult males.
In order for tadalafil to be effective, sexual stimulation is
required.
Tadalafil Mylan is not indicated for use by women.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adult men_
In general, the recommended dose is 10 mg taken prior to anticipated
sexual activity and with or without
food.
In those patients in whom tadalafil 10 mg does not produce an adequate
effect, 20 mg might be tried.
It may be taken at least 30 minutes prior to sexual activity.
The maximum dose frequency is once per day.
Tadalafil 10 and 20 mg is intended for use prior to anticipated sexual
activity and it is not recommended for
continuous daily use.
In patients who anticipate a frequent use of tadalafil (i.e., at least
twice weekly) a once daily regimen with
the lowest doses of tadalafil might be considered suitable, based on
patient choice and the physician’s
judgement.
In these patients the recommended dose is 5 mg taken once a day at
approximately the same time of day. The
dose may be decreased to 2.5 mg once a day based on individual
tolerability.
The appropriateness of continued use of the daily regimen should be
reassessed periodically.
3
Special populations
_Elderly men_
Dose adjustments are not required in elderly patients.
_Men with renal impairment_
Dose adjustments are not required in patients with mild to moderate
renal impairment. For patients with
severe renal impairment 10 mg is t
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Foglio illustrativo Foglio illustrativo bulgaro 30-06-2022
Scheda tecnica Scheda tecnica bulgaro 30-06-2022
Foglio illustrativo Foglio illustrativo spagnolo 30-06-2022
Scheda tecnica Scheda tecnica spagnolo 30-06-2022
Relazione pubblica di valutazione Relazione pubblica di valutazione spagnolo 19-12-2014
Foglio illustrativo Foglio illustrativo ceco 30-06-2022
Scheda tecnica Scheda tecnica ceco 30-06-2022
Foglio illustrativo Foglio illustrativo danese 30-06-2022
Scheda tecnica Scheda tecnica danese 30-06-2022
Foglio illustrativo Foglio illustrativo tedesco 30-06-2022
Scheda tecnica Scheda tecnica tedesco 30-06-2022
Foglio illustrativo Foglio illustrativo estone 30-06-2022
Scheda tecnica Scheda tecnica estone 30-06-2022
Foglio illustrativo Foglio illustrativo greco 30-06-2022
Scheda tecnica Scheda tecnica greco 30-06-2022
Foglio illustrativo Foglio illustrativo francese 30-06-2022
Scheda tecnica Scheda tecnica francese 30-06-2022
Relazione pubblica di valutazione Relazione pubblica di valutazione francese 19-12-2014
Foglio illustrativo Foglio illustrativo italiano 30-06-2022
Scheda tecnica Scheda tecnica italiano 30-06-2022
Relazione pubblica di valutazione Relazione pubblica di valutazione italiano 19-12-2014
Foglio illustrativo Foglio illustrativo lettone 30-06-2022
Scheda tecnica Scheda tecnica lettone 30-06-2022
Foglio illustrativo Foglio illustrativo lituano 30-06-2022
Scheda tecnica Scheda tecnica lituano 30-06-2022
Foglio illustrativo Foglio illustrativo ungherese 30-06-2022
Scheda tecnica Scheda tecnica ungherese 30-06-2022
Relazione pubblica di valutazione Relazione pubblica di valutazione ungherese 19-12-2014
Foglio illustrativo Foglio illustrativo maltese 30-06-2022
Scheda tecnica Scheda tecnica maltese 30-06-2022
Foglio illustrativo Foglio illustrativo olandese 30-06-2022
Scheda tecnica Scheda tecnica olandese 30-06-2022
Relazione pubblica di valutazione Relazione pubblica di valutazione olandese 19-12-2014
Foglio illustrativo Foglio illustrativo polacco 30-06-2022
Scheda tecnica Scheda tecnica polacco 30-06-2022
Foglio illustrativo Foglio illustrativo portoghese 30-06-2022
Scheda tecnica Scheda tecnica portoghese 30-06-2022
Relazione pubblica di valutazione Relazione pubblica di valutazione portoghese 19-12-2014
Foglio illustrativo Foglio illustrativo rumeno 30-06-2022
Scheda tecnica Scheda tecnica rumeno 30-06-2022
Foglio illustrativo Foglio illustrativo slovacco 30-06-2022
Scheda tecnica Scheda tecnica slovacco 30-06-2022
Relazione pubblica di valutazione Relazione pubblica di valutazione slovacco 19-12-2014
Foglio illustrativo Foglio illustrativo sloveno 30-06-2022
Scheda tecnica Scheda tecnica sloveno 30-06-2022
Foglio illustrativo Foglio illustrativo finlandese 30-06-2022
Scheda tecnica Scheda tecnica finlandese 30-06-2022
Relazione pubblica di valutazione Relazione pubblica di valutazione finlandese 19-12-2014
Foglio illustrativo Foglio illustrativo svedese 30-06-2022
Scheda tecnica Scheda tecnica svedese 30-06-2022
Foglio illustrativo Foglio illustrativo norvegese 30-06-2022
Scheda tecnica Scheda tecnica norvegese 30-06-2022
Foglio illustrativo Foglio illustrativo islandese 30-06-2022
Scheda tecnica Scheda tecnica islandese 30-06-2022
Foglio illustrativo Foglio illustrativo croato 30-06-2022
Scheda tecnica Scheda tecnica croato 30-06-2022

Cerca alert relativi a questo prodotto

Visualizza cronologia documenti